Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 15/20 | 0.71 |
| ▸ | SMARCA4 | P51532 | 15/20 | 0.71 |
| ▸ | PBRM1 | Q86U86 | 15/20 | 0.71 |
| ▸ | NR1I2 | O75469 | 9/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.46 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606905 | 1.00 | SMARCA2 (0.71) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL30606896 | 0.94 | PBRM1 (0.66) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL18038859 | 0.94 | PBRM1 (0.66) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL31548738 | 0.87 | SMARCA2 (0.65) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL18080998 | 0.85 | PBRM1 (0.51) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL23037244 | 0.85 | PBRM1 (0.54) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL27461434 | 0.85 | SMARCA2 (0.62) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL30797067 | 0.85 | SMARCA2 (0.62) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL18038815 | 0.85 | PBRM1 (0.59) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 | |
| SCHEMBL30606964 | 0.85 | PBRM1 (0.59) | SMARCA2SMARCA4PBRM1NR1I2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3262036-B1 | THERAPEUTIC PYRIDAZINE COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-107531668-B | Therapeutic pyridazine compounds and uses thereof | 基因泰克公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | SMARCA2 10/4885SMARCA4 3/4885PBRM1 11/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SMARCA2 10/4885SMARCA4 3/4885PBRM1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.